Aplastic anemia

Aplastic anemia
Name	Aplastic anemia

Aplastic anemia is a rare hematologic disorder characterized by pancytopenia and a hypocellular bone marrow leading to failure of hematopoiesis. It presents acutely or chronically, may follow exposure to drugs, toxins, infections, or immune dysregulation, and is managed with immunosuppression, hematopoietic stem cell transplantation, or supportive care. Recognition and timely treatment influence outcomes in settings ranging from tertiary centers to global public health programs.

Signs and symptoms

Patients typically present with fatigue, pallor, bleeding, and infections due to anemia, thrombocytopenia, and neutropenia respectively. Common manifestations include dyspnea on exertion, palpitations, mucosal petechiae, epistaxis, gingival bleeding, and recurrent bacterial, viral, or fungal infections. Physical examination may show conjunctival pallor, tachycardia, and petechiae but often lacks organomegaly, distinguishing it from conditions that cause splenomegaly. Severe cases may progress to life-threatening hemorrhage or sepsis requiring admission to intensive care units and interventions such as transfusion support or antimicrobial therapy.

Causes and pathophysiology

Aplastic anemia arises from destruction or suppression of hematopoietic stem and progenitor cells in the bone marrow. Etiologies include drug-induced marrow aplasia from agents such as chloramphenicol, benzene, and certain antiepileptics; radiation exposure from therapeutic or environmental sources; and viral infections including hepatitis viruses, Epstein–Barr virus, and parvovirus B19. Immune-mediated mechanisms, notably autoreactive cytotoxic T lymphocytes, are central in idiopathic cases and may be associated with thymoma or autoimmune disorders. Inherited bone marrow failure syndromes such as Fanconi anemia, dyskeratosis congenita, and Shwachman–Diamond syndrome share overlapping pathways involving DNA repair, telomere maintenance, and ribosomal biogenesis. Pathophysiology involves cytokine dysregulation, marrow microenvironment injury, and clonal evolution to myelodysplastic syndromes or acute leukemia in a subset of patients.

Diagnosis

Diagnosis is established with peripheral blood counts showing pancytopenia and a bone marrow biopsy demonstrating hypocellularity without marrow fibrosis or malignant infiltration. Laboratory evaluation includes reticulocyte count, serum iron studies, viral serologies, and tests for inherited disorders such as chromosomal breakage analysis and telomere length assays. Flow cytometry may detect paroxysmal nocturnal hemoglobinuria clones; cytogenetics and next-generation sequencing can identify clonal cytopenias or mutations associated with prognosis. Differential diagnosis incorporates myelodysplastic syndromes, acute leukemia, hypersplenism, and nutritional deficiencies; collaboration with hematopathology services and tertiary referral centers often involves hematopoietic transplantation programs and specialized laboratories.

Treatment

Management strategies include supportive care with red cell and platelet transfusions and antimicrobial prophylaxis or therapy guided by infectious disease protocols. First-line disease-modifying therapies comprise hematopoietic stem cell transplantation from matched related or unrelated donors for eligible patients, and immunosuppressive therapy such as antithymocyte globulin combined with cyclosporine for those without suitable donors or with contraindications to transplant. Growth factors like granulocyte colony-stimulating factor may be used adjunctively. Novel approaches under investigation include eltrombopag, gene therapy for inherited marrow failure syndromes, and reduced-intensity conditioning transplant regimens developed in cooperation with transplant centers. Treatment decisions are influenced by patient age, comorbidities, donor availability, and resources at transplant centers or regional referral hospitals.

Prognosis and complications

Prognosis varies with etiology, age, and treatment: younger patients receiving matched sibling transplantation have the best long-term survival, whereas older patients or those with refractory disease face higher morbidity and mortality. Complications include severe infections, hemorrhage from thrombocytopenia, iron overload from chronic transfusions requiring chelation therapy, and clonal evolution to myelodysplastic syndrome or acute myeloid leukemia. Late effects in transplant survivors may include chronic graft-versus-host disease and secondary malignancies; ongoing follow-up in oncology and transplant clinics is essential for surveillance and management.

Epidemiology and prevention

Aplastic anemia incidence shows geographic variation with higher rates reported in parts of Asia compared with Europe and North America; it affects all ages but has bimodal peaks in childhood and older adulthood. Population-based estimates and registry data inform public health strategies, occupational safety regulations to limit benzene and solvent exposure, vaccination and viral hepatitis control programs, and pharmacovigilance for drugs implicated in marrow toxicity. Preventive measures include workplace exposure limits, stewardship of medications with hematologic risks, screening for inherited marrow failure in affected families, and coordination with international health organizations and transplant networks to improve access to definitive therapies.

Category:Hematology